Preparation of highly specific monoclonal antibodies against SARS‐CoV‐2 nucleocapsid protein and the preliminary development of antigen detection test strips. Issue 4 (21st December 2021)

• Record Type: Journal Article
• Authors: Xie, Chengzuo; Ding, Haojie; Ding, Jianzu; Xue, Yangji; Lu, Shaohong; Lv, Hangjun
• Other Names: Luo Guangxiang (George) guestEditor.; Ly Hinh guestEditor.; Gao Shou‐Jiang guestEditor.
• Is Part Of: Journal of medical virology. Volume 94:Issue 4(2022)
• Page Start: 1633
• Page End: 1640
• Publication Date: 2021-12-21
• Subjects: colloidal gold immunochromatography -- Delta (B.1.617.2) variant -- recombinant SARS‐CoV‐2 nucleocapsid protein -- SARS‐CoV‐2 -- the monoclonal antibodies; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.27520
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: The coronavirus disease 2019 (COVID‐19) is outbreaking all over the world. To help fight this disease, it is necessary to establish an effective and rapid detection method. The nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is involved in viral replication, assembly, and immune regulation and plays an important role in the viral life cycle. Moreover, the N protein also could be a diagnostic factor and potential drug target. Therefore, by synthesizing the N gene sequence of SARS‐CoV‐2, constructing the pET‐28a (+)‐N recombinant plasmid, we expressed the N protein in Escherichia coli and obtained 15 monoclonal antibody (mAbs) against SARS‐CoV‐2‐N protein by the hybridomas and ascites, then an immunochromatographic test strip method detecting N antigen was established. In this study, we obtained 14 high‐titer and high‐specificity monoclonal antibodies, and the test strips exclusively react with the SARS‐CoV‐2‐N protein and no cross‐reactivity with other coronavirus and also recognize the recombinant N protein of Delta (B.1.617.2) variant. These mAbs can be used for the early and rapid diagnosis of SARS‐CoV‐2 infection through serological antigen.